XML 46 R33.htm IDEA: XBRL DOCUMENT
v3.21.2

Operating Segments (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2021
Segment Reporting [Abstract] |
Schedule of Segment Reporting Information | The table below presents certain financial information of our operating segments for the three and nine months ended September 30, 2021 and 2020 (in thousands). Schedule of Segment Reporting Information Segment Reporting for the Quarter Ended September 30, 2021
|  | Treatment |  |  | Services |  |  | Medical |  |  | Segments Total |  |  | Corporate (1) |  |  | Consolidated Total |
|  | Treatment |  |  | Services |  |  | Medical |  |  | Segments Total |  |  | Corporate (1) |  |  | Consolidated Total |
Revenue from external customers |  | $ | 8,893 |  |  | $ | 6,904 |  |  |  | — |  |  | $ | 15,797 |  |  | $ | — |  |  | $ | 15,797 |
Intercompany revenues |  |  | 220 |  |  |  | 5 |  |  |  | — |  |  |  | 225 |  |  |  | — |  |  |  | — |
Gross profit (negative gross profit) |  |  | 2,487 |  |  |  | (263 | ) |  |  | — |  |  |  | 2,224 |  |  |  | — |  |  |  | 2,224 |
Research and development |  |  | 52 |  |  |  | 18 |  |  |  | 162 |  |  |  | 232 |  |  |  | 11 |  |  |  | 243 |
Interest income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 2 |  |  |  | 2 |
Interest expense |  |  | (51 | ) |  |  | (1 | ) |  |  | — |  |  |  | (52 | ) |  |  | (25 | ) |  |  | (77 | )
Interest expense-financing fees |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (11 | ) |  |  | (11 | )
Depreciation and amortization |  |  | 319 |  |  |  | 85 |  |  |  | — |  |  |  | 404 |  |  |  | 5 |  |  |  | 409 |
Segment income (loss) before income taxes |  |  | 1,317 |  |  |  | (984 | ) |  |  | (162 | ) |  |  | 171 |  |  |  | (1,626 | ) |  |  | (1,455 | )
Income tax expense (benefit) |  |  | 1 |  |  |  | — |  |  |  | — |  |  |  | 1 |  |  |  | (2,837 | ) |  |  | (2,836 | )(5)
Segment income (loss) |  |  | 1,316 |  |  |  | (984 | ) |  |  | (162 | ) |  |  | 170 |  |  |  | 1,211 |  |  |  | 1,381 |
Expenditures for segment assets |  |  | 482 |  |  |  | — |  |  |  | — |  |  |  | 482 |  |  |  | — |  |  |  | 482 | (2)
Segment Reporting for the Quarter Ended September 30, 2020
|  | Treatment |  |  | Services |  |  | Medical |  |  | Segments Total |  |  | Corporate (1) |  |  | Consolidated Total |
|  | Treatment |  |  | Services |  |  | Medical |  |  | Segments Total |  |  | Corporate (1) |  |  | Consolidated Total |
Revenue from external customers |  | $ | 7,066 |  |  | $ | 23,106 |  |  |  | — |  |  | $ | 30,172 |  |  | $ | — |  |  | $ | 30,172 |
Intercompany revenues |  |  | 226 |  |  |  | 6 |  |  |  | — |  |  |  | 232 |  |  |  | — |  |  |  | — |
Gross profit |  |  | 1,094 |  |  |  | 3,656 |  |  |  | — |  |  |  | 4,750 |  |  |  | — |  |  |  | 4,750 |
Research and development |  |  | 49 |  |  |  | 7 |  |  |  | 81 |  |  |  | 137 |  |  |  | 20 |  |  |  | 157 |
Interest income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 28 |  |  |  | 28 |
Interest expense |  |  | (34 | ) |  |  | (3 | ) |  |  | — |  |  |  | (37 | ) |  |  | (50 | ) |  |  | (87 | )
Interest expense-financing fees |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (58 | ) |  |  | (58 | )
Depreciation and amortization |  |  | 373 |  |  |  | 97 |  |  |  | — |  |  |  | 470 |  |  |  | 8 |  |  |  | 478 |
Segment income (loss) before income taxes |  |  | 280 |  |  |  | 2,813 |  |  |  | (81 | ) |  |  | 3,012 |  |  |  | (1,664 | ) |  |  | 1,348 |
Income tax (benefit) expense |  |  | (170 | ) |  |  | 2 |  |  |  | — |  |  |  | (168 | ) |  |  | 35 |  |  |  | (133 | )
Segment income (loss) |  |  | 450 |  |  |  | 2,811 |  |  |  | (81 | ) |  |  | 3,180 |  |  |  | (1,699 | ) |  |  | 1,481 |
Expenditures for segment assets |  |  | 95 |  |  |  | 24 |  |  |  | — |  |  |  | 119 |  |  |  | 3 |  |  |  | 122 | (3)
Segment Reporting for the Nine Months Ended September 30, 2021
|  | Treatment |  |  | Services |  |  | Medical |  |  | Segments Total |  |  | Corporate (1) |  |  | Consolidated Total |
|  | Treatment |  |  | Services |  |  | Medical |  |  | Segments Total |  |  | Corporate (1) |  |  | Consolidated Total |
Revenue from external customers |  | $ | 24,094 |  |  | $ | 30,981 |  |  |  | — |  |  | $ | 55,075 |  |  | $ | — |  |  | $ | 55,075 |
Intercompany revenues |  |  | 1,199 |  |  |  | 44 |  |  |  | — |  |  |  | 1,243 |  |  |  | — |  |  |  | — |
Gross profit |  |  | 4,845 |  |  |  | 701 |  |  |  | — |  |  |  | 5,546 |  |  |  | — |  |  |  | 5,546 |
Research and development |  |  | 142 |  |  |  | 50 |  |  |  | 311 |  |  |  | 503 |  |  |  | 35 |  |  |  | 538 |
Interest income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 23 |  |  |  | 23 |
Interest expense |  |  | (88 | ) |  |  | (9 | ) |  |  | — |  |  |  | (97 | ) |  |  | (112 | ) |  |  | (209 | )
Interest expense-financing fees |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (28 | ) |  |  | (28 | )
Depreciation and amortization |  |  | 939 |  |  |  | 255 |  |  |  | — |  |  |  | 1,194 |  |  |  | 14 |  |  |  | 1,208 |
Segment income (loss) before income taxes |  |  | 1,669 |  |  |  | (1,721 | ) |  |  | (311 | ) |  |  | (363 | ) |  |  | 987 | (4) |  |  | 624 |
Income tax (benefit) expense |  |  | (13 | ) |  |  | 10 |  |  |  | — |  |  |  | (3 | ) |  |  | (2,837 | ) |  |  | (2,840 | )(5)
Segment income (loss) |  |  | 1,682 |  |  |  | (1,731 | ) |  |  | (311 | ) |  |  | (360 | ) |  |  | 3,824 |  |  |  | 3,464 |
Expenditures for segment assets |  |  | 1,109 |  |  |  | 14 |  |  |  | — |  |  |  | 1,123 |  |  |  | 9 |  |  |  | 1,132 | (2)
Segment Reporting for the Nine Months Ended September 30, 2020
|  | Treatment |  |  | Services |  |  | Medical |  |  | Segments Total |  |  | Corporate (1) |  |  | Consolidated Total |
|  | Treatment |  |  | Services |  |  | Medical |  |  | Segments Total |  |  | Corporate (1) |  |  | Consolidated Total |
Revenue from external customers |  | $ | 24,469 |  |  | $ | 52,610 |  |  |  | — |  |  | $ | 77,079 |  |  | $ | — |  |  | $ | 77,079 |
Intercompany revenues |  |  | 879 |  |  |  | 19 |  |  |  | — |  |  |  | 898 |  |  |  | — |  |  |  | — |
Gross profit |  |  | 5,533 |  |  |  | 7,167 |  |  |  | — |  |  |  | 12,700 |  |  |  | — |  |  |  | 12,700 |
Research and development |  |  | 194 |  |  |  | 119 |  |  |  | 221 |  |  |  | 534 |  |  |  | 64 |  |  |  | 598 |
Interest income |  |  | 1 |  |  |  | — |  |  |  | — |  |  |  | 1 |  |  |  | 111 |  |  |  | 112 |
Interest expense |  |  | (80 | ) |  |  | (13 | ) |  |  | — |  |  |  | (93 | ) |  |  | (213 | ) |  |  | (306 | )
Interest expense-financing fees |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (187 | ) |  |  | (187 | )
Depreciation and amortization |  |  | 912 |  |  |  | 259 |  |  |  | — |  |  |  | 1,171 |  |  |  | 18 |  |  |  | 1,189 |
Segment income (loss) before income taxes |  |  | 2,577 |  |  |  | 5,162 |  |  |  | (221 | ) |  |  | 7,518 |  |  |  | (4,597 | ) |  |  | 2,921 |
Income tax (benefit) expense |  |  | (165 | ) |  |  | 2 |  |  |  | — |  |  |  | (163 | ) |  |  | 35 |  |  |  | (128 | )
Segment income (loss) |  |  | 2,742 |  |  |  | 5,160 |  |  |  | (221 | ) |  |  | 7,681 |  |  |  | (4,632 | ) |  |  | 3,049 |
Expenditures for segment assets |  |  | 1,095 |  |  |  | 385 |  |  |  | — |  |  |  | 1,480 |  |  |  | 8 |  |  |  | 1,488 | (3)
(1) |  | Amounts reflect the activity for corporate headquarters not included in the segment information.
(2) |  | Net of financed amount of $271,000 and $348,000 for the three and nine months ended September 30, 2021, respectively.
(3) |  | Net of financed amount of $751,000 and $883,000 for the three and nine months ended September 30, 2020, respectively.
(4) |  | Amounts includes approximately $5,381,000 of “Gain on extinguishment of debt” recorded in connection with the Company’s PPP Loan which was forgiven by the SBA effective June 15, 2021 (see “Note 8 – Long Term Debt – PPP Loan” for information of this loan forgiveness).
(5) |  | Includes tax benefit recorded in amount of approximately $2,351,000 resulting from release of valuation allowance on the Company’s deferred tax assets (see “Note 12 – Income Taxes” below a discussion of this tax benefit).

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration